ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1550

Change in Tophus Size Measured with Dual-energy CT and Ultrasound: A 1-year Multicenter Follow-up Study

Tristan Pascart1, Pascal Richette2, Sebastien Ottaviani3, Laurène Norberciak1, Hang Korng EA4, Frédéric Lioté5, Jérémy Ora6, Julie Legrand1, Valérie Bousson6, Elyas Mahdjoub7 and Jean--Francois Budzik8, 1GHICL, Lomme, France, 2Department of Rheumatology, Lariboisière Hospital, Paris, France, 3Rheumatology Department, Bichat hospital, APHP, Paris, France, 4Universite de Paris, AP-HP, INSERM, paris, France, 5AP-HP, Paris, France, 6Lariboisière Hospital, Paris, France, 7Bichat Hospital, Paris, France, 8University of Lille, Lille, France

Meeting: ACR Convergence 2020

Keywords: Computed tomography (CT), gout, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Dual-Energy computed tomography (DECT) and ultrasound are the two techniques able to identify and measure monosodium urate (MSU) crystal deposition, and both are considered for monitoring crystal depletion during urate lowering therapy (ULT). Particularly, both techniques are able to measure tophi, but it is unknown if their assessment of tophus size are correlated throughout follow-up. The objective of this study was to determine if the evolution of tophus volume measured with DECT and ultrasound were correlated during the first year of ULT.

Methods: Gout patients naïve of ULT and presenting with at least 1 ultrasound tophus of the knees or ankles/feet were recruited in three French referral centers to undergo DECT scans, and were followed-up with ultrasound and DECT scans at months 6 and 12. The largest tophus in ultrasound was considered as the index tophus and measured with both techniques. The primary endpoint was the correlation between the evolution of the volumes of the index tophus measured with DECT and ultrasound assessed by the Spearman coefficient correlation (ρ) and its 95% confidence interval at months 6 and 12.

Results: A total of 41 patients were included; they were mostly males (83.3%) and aged in average 63.7 years (±12.3). Baseline serum urate levels were 515.2 µmol/L (±85) (=8.6mg/dL) and 58.3% had subcutaneous tophi. Most index tophi were localized at the 1st MTP joint (53.9%) and had a volume of 0.87 cm3 (±1.39). 17 patients were lost to follow-up and 4 patients had index tophi that were not detected by DECT at baseline. The relative decrease of the volume of the index tophi at months 6 and 12 measured with ultrasound was -50% [-79.2%;0%] and -75.6% [-94.2%;-25%], respectively, while the decrease measured with DECT was -32.1% [-85.8%;0%] and -37.1% [-88.5%;0%], respectively.

The correlation between the volumes of the index tophi measured with ultrasound and DECT was poor with ρ=0.29 [-0.22;0.65] at month 6 and ρ=-0.03 [-0.66;0.65] at month 12. The correlation between the decrease of the DECT tophus index volume and the global volume of MSU crystal deposition measured with DECT was very good at both months 6 and 12 with ρ=0.82 [0.55;0.93] and 0.83 [0.5;0.96]. The correlation between the decrease of the volume of the index tophus measured with ultrasound and the decrease of the volume of overall MSU crystal deposition measured with DECT was at best moderate with ρ=0.35 [-0.16;0.75] at month 6 and 0.42 [-0.44 ; 0.82] at month 12.

Conclusion: Ultrasound and DECT do not provide the same assessment of MSU crystal depletion during the first year of ULT. The two techniques are not inter-changeable when considering monitoring gout treatment with imaging, especially when considering the follow-up of a target tophus.

Figure 1. Evolution (in % from baseline) at month 6 of the index tophus measured with dual-energy computed tomography (DECT) and ultrasound.


Disclosure: T. Pascart, Horizon Therapeutics, 2, Novartis, 8; P. Richette, AbbVie Inc., 1, Biogen, 1, Janssen, 1, BMS, 1, Roche, 1, Pfizer, 1, Amgen, 1, Sanofi-Aventis, 1, UCB, 1, Lilly, 1, Novartis, 1, Celgene, 1; S. Ottaviani, None; L. Norberciak, None; H. EA, None; F. Lioté, LILLY FRANCE, 5, 8, SANOFI GENZYME, 8, SANDOZ, 5, NORDIC PHARMA, 8, LILLY FRANCE, 3; J. Ora, None; J. Legrand, None; V. Bousson, None; E. Mahdjoub, None; J. Budzik, None.

To cite this abstract in AMA style:

Pascart T, Richette P, Ottaviani S, Norberciak L, EA H, Lioté F, Ora J, Legrand J, Bousson V, Mahdjoub E, Budzik J. Change in Tophus Size Measured with Dual-energy CT and Ultrasound: A 1-year Multicenter Follow-up Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/change-in-tophus-size-measured-with-dual-energy-ct-and-ultrasound-a-1-year-multicenter-follow-up-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/change-in-tophus-size-measured-with-dual-energy-ct-and-ultrasound-a-1-year-multicenter-follow-up-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology